Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: A retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects

Diabetic Medicine

Volumn 27, Issue 10, 2010, Pages 1168-1173

  Ellero, C ^a   Han, J ^a   Bhavsar, S ^a   Cirincione, B B ^a   Deyoung, M B ^a   Gray, A L ^b   Yushmanova, I ^a   Anderson, P W ^b  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b Lilly USA   (United States)

Author keywords

anti emetics; exenatide; nausea; vomiting

Indexed keywords

EXENDIN 4; METOCLOPRAMIDE; ONDANSETRON;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PROPHYLAXIS; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIEMETICS; AREA UNDER CURVE; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NAUSEA; PEPTIDES; UNITED STATES; VENOMS; VOMITING; YOUNG ADULT;

EID: 77956832959     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03085.x     Document Type: Article

References (12)

1. Amylin Pharmaceuticals Inc. BYETTA® exenatide injection (prescribing information). San Diego, CA : Amylin Pharmaceuticals Inc., 2009.
2. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008 30 : 1448 1460. Published correction appears in Clin Ther 2008 30 : 1937.
3. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 28 : 1083 1091.
4. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 27 : 2628 2635.
5. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005 28 : 1092 1100.
6. Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007 146 : 477 485. Published correction appears in Ann Intern Med. 2007 146 : 896.
7. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004 20 : 411 417.
8. Peters AL, Miller D. Case study 2: new insights: clinical pearls for using incretin mimetics in type 2 diabetes. Diabetes Educ 2007 33 : 14S 19S.
9. Alaven Pharmaceutical LLC. Reglan® metoclopramide hydrochloride tablets (prescribing information). Marietta, GA : Alaven Pharmaceutical LLC, 2009.
10. GlaxoSmithKline. Zofran (ondansetron hydrochloride) tablets (prescribing information). Research Triangle Park, NC : GlaxoSmithKline, 2009.
11. Siminerio L. Challenges and strategies for moving patients to injectable medications. Diabetes Educ 2006 32 : 82S 90S.
12. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research & Opinion 2008 24 : 275 286.